The integration of four major determinants of antibiotic action: Bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 579-583

  Li, Ronald C ^a,c   Zhu, Z Y ^a,b  

^a Prince of Wales Hospital   (Hong Kong)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bactericidal activity; PAE; Pharmacodynamics; Pharmacokinetics,; PK PD; Postantibiotic effect; Tobramycin

Indexed keywords

TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; STRAIN DIFFERENCE;

EID: 0036975231     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.579     Document Type: Article

References (10)

1. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, eds. Antibiotics in laboratory Medicine, 4th ed. Baltimore, MD: Williams & Wilkins. 1996: 296-329.
2. Li RC, Zhu ZY, Lee SW, Raymond K, Ling JML, Cheng AFB. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41:1808-1811.
3. Li RC, Lee SW, Kong CH. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. J Antimicrob Chemother 1997; 40: 39-45.
4. Vogelman BS, Gudmundsson S, Leggett J. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
5. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects: Focus on aminoglycosides. Clin Pharmacokinet 1994; 27: 377-392.
6. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399-405.
7. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 1-17.
8. Grasso S, Meinardi G, De Cameri I, Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 1978; 4: 570-576.
9. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991; 25: 1050-1057.
10. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993; 37: 1073-1081.